Mogadon

Sleep disorders of different genesis (difficulty falling asleep, frequent night and/or early morning awakenings); encephalopathy, accompanied by myoclonic seizures (as a part of combination therapy), epilepsy in children at the age from 4 months to 1-2 years old – West syndrome (infantile spasms or lighting salaam spasms); neuroses, psychopathy, chronic alcoholism, endogenous psychosis, organic CNS diseases (as a part of combination therapy); premedication.

Contraindications

Hypersensitivity, coma, shock, acute alcohol intoxication with the depression of vital functions, acute drug intoxications, which have depressant effects on CNS (including narcotic analgesics and sleeping pills); drug addiction, alcoholism; myasthenia gravis; angle-closure glaucoma (acute attack or predisposition); temporal lobe epilepsy, severe COPD (progressive degree of respiratory failure), acute respiratory failure, hypercapnia, severe depression (with possible suicidal tendencies), trouble swallowing in children, pregnancy (especially I trimester), lactation period.

With caution

Renal or respiratory failure, cerebral or spinal ataxia, hyperkinesis, drug addiction in anamnesis, prone to the substance abuse, organic brain diseases, psychosis (possible paradoxical reactions), hypoproteinemia, sleep apnea (diagnosed or estimated), old age.

Directions for use and doses

Orally. As a soporific drug 1/2 hours before bed: adults – 5-10 mg, old patients – 2.5-5 mg; children under 1 year – 1.25-2.5 mg before bed; from 1 to 6 years – 2.5-5 mg before bed; from 6 to 14 years – 5 mg before bed. Maximal single dose as a soporific drug for adults – 20 mg.

As anxiolytic and anti-epilepsy drugs: adults – 5-10 mg 2-3 times a day. Maximal daily dose – 30 mg.

Daily dose for infants – 2.5-7.5 mg, in early childhood – 5-10 mg, at school age – 7.5-15 mg 2-3 times a day, for the children weighing less than 30 kg – 0.3-1 mg/kg a day 3 times a day; at that, a larger part of dose must be taken in the evening before bed.

During treatment it is strictly prohibited to take ethanol. The drug should not be used long without specific instructions. In case of renal/liver failure and long-term treatment, it is necessary to control the picture of peripheral blood and “liver” enzymes. The risk of developing drug addiction is increasing in case of high dosage, long duration of treatment, in patients, previously abusing ethanol or drugs. Mogadon has a foundational capacity for developing addiction. If you use it daily for several weeks, there is a risk of developing physical and mental addiction. It develops not only in case of abusing nitrazepam (especially high doses), but also if it is used in usual therapeutic doses. So, the treatment should be continued only if it is vitally important, after the careful comparison of the treatment benefit with the risk of developing drug addiction. In this case, the abrupt withdrawal is accompanied with the withdrawal syndrome(headache, myalgia, anxiety, tension, confusion, irritability; in severe cases – derealization, depersonalization disorder, hyperacusis, photophobia, paresthesia of extremities; hallucinations and epileptic seizures). The drug withdrawal must be carried out gradually. If the patients have such unusual reactions as increased aggressiveness, acute states of agitation, fear, suicidal thoughts, hallucinations, increases of muscle cramps, difficulty falling asleep, superficial sleep, you should stop taking nitrazepam.